{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:19:55Z","timestamp":1791566395047,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["Novartis Pharmaceuticals Corporation"],"award-info":[{"award-number":["Novartis Pharmaceuticals Corporation"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-024-05736-6","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T04:01:42Z","timestamp":1713585702000},"page":"1909-1917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND\/UCLA modified Delphi panel"],"prefix":"10.1007","volume":"103","author":[{"given":"Julie","family":"Kanter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Ataga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Kutlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lanzkron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Manwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McGann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Stowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ven\u00e9e N.","family":"Tubman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Yermilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"5736_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21570","author":"DC Brousseau","year":"2009","unstructured":"Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG (2009) The number of people with sickle cell disease in the United States: National and state estimates. Am J Hematol NA-NA. https:\/\/doi.org\/10.1002\/ajh.21570","journal-title":"Am J Hematol NA-NA"},{"key":"5736_CR2","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","volume":"38","author":"KL Hassell","year":"2010","unstructured":"Hassell KL (2010) Population estimates of Sickle Cell Disease in the U.S. Am J Prev Med 38:S512\u2013S521. https:\/\/doi.org\/10.1016\/j.amepre.2009.12.022","journal-title":"Am J Prev Med"},{"key":"5736_CR3","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","volume":"115","author":"CT Quinn","year":"2010","unstructured":"Quinn CT, Rogers ZR, McCavit TL, Buchanan GR (2010) Improved survival of children and adolescents with sickle cell disease. Blood 115:3447\u20133452. https:\/\/doi.org\/10.1182\/blood-2009-07-233700","journal-title":"Blood"},{"key":"5736_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/gim.2014.123","volume":"17","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu G, Caggana M et al (2015) Mortality of New York children with sickle cell disease identified through newborn screening. Genet Med 17:452\u2013459. https:\/\/doi.org\/10.1038\/gim.2014.123","journal-title":"Genet Med"},{"key":"5736_CR5","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1111\/bjh.16314","volume":"188","author":"C Nze","year":"2020","unstructured":"Nze C, Fortin B, Freedman R et al (2020) Sudden death in sickle cell disease: current experience. Br J Haematol 188:e43\u2013e45. https:\/\/doi.org\/10.1111\/bjh.16314","journal-title":"Br J Haematol"},{"key":"5736_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J et al (2017) Crizanlizumab for the Prevention of Pain crises in Sickle Cell Disease. N Engl J Med 376:429\u2013439. https:\/\/doi.org\/10.1056\/NEJMoa1611770","journal-title":"N Engl J Med"},{"key":"5736_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajh.25308","volume":"94","author":"A Kutlar","year":"2019","unstructured":"Kutlar A, Kanter J, Liles DK et al (2019) Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol 94:55\u201361. https:\/\/doi.org\/10.1002\/ajh.25308","journal-title":"Am J Hematol"},{"key":"5736_CR8","unstructured":"Novartis Pharmaceuticals Corporation ADAKVEO\u00ae (crizanlizumab-tmca) injection, for intravenous use [Prescribing Information]"},{"key":"5736_CR9","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1182\/blood-2021-154355","volume":"138","author":"VJ Li","year":"2021","unstructured":"Li VJ, Adesina OO, Fertrin KY (2021) Crizanlizumab-Associated painful febrile reaction in Sickle Cell Disease patients. Blood 138:4186. https:\/\/doi.org\/10.1182\/blood-2021-154355","journal-title":"Blood"},{"key":"5736_CR10","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2021-152362","volume":"138","author":"J Kanter","year":"2021","unstructured":"Kanter J, Shah A, Joshi V et al (2021) Rare cases of infusion-related reactions (IRRs) presenting as Pain events during or after Crizanlizumab infusion in patients (pts) with sickle cell disease (SCD): a systematic evaluation of Post-marketing (PM) reports. Blood 138:3112. https:\/\/doi.org\/10.1182\/blood-2021-152362","journal-title":"Blood"},{"key":"5736_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","volume":"5","author":"M Picard","year":"2017","unstructured":"Picard M, Galv\u00e3o VR (2017) Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract 5:600\u2013609. https:\/\/doi.org\/10.1016\/j.jaip.2016.12.001","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5736_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/0272989X211028236","volume":"42","author":"L Bojke","year":"2022","unstructured":"Bojke L, Soares MO, Claxton K et al (2022) Reference case methods for Expert Elicitation in Health Care decision making. Med Decis Mak 42:182\u2013193. https:\/\/doi.org\/10.1177\/0272989X211028236","journal-title":"Med Decis Mak"},{"key":"5736_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev-pathol-042320-110411","volume":"18","author":"CM Arthur","year":"2023","unstructured":"Arthur CM, Stowell SR (2023) The Development and consequences of Red Blood Cell Alloimmunization. Annu Rev Pathol Mech Dis 18:537\u2013564. https:\/\/doi.org\/10.1146\/annurev-pathol-042320-110411","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"5736_CR14","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.3324\/haematol.2020.262006","volume":"105","author":"S Chonat","year":"2020","unstructured":"Chonat S, Graciaa S, Shin HS et al (2020) Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease. Haematologica 105:2887\u20132891. https:\/\/doi.org\/10.3324\/haematol.2020.262006","journal-title":"Haematologica"},{"key":"5736_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.tmrv.2019.09.007","volume":"33","author":"LT Roumenina","year":"2019","unstructured":"Roumenina LT, Bartolucci P, Pirenne F (2019) The role of complement in Post-transfusion Hemolysis and Hyperhemolysis reaction. Transfus Med Rev 33:225\u2013230. https:\/\/doi.org\/10.1016\/j.tmrv.2019.09.007","journal-title":"Transfus Med Rev"},{"key":"5736_CR16","doi-asserted-by":"publisher","first-page":"E338","DOI":"10.1002\/ajh.26002","volume":"95","author":"K Karkoska","year":"2020","unstructured":"Karkoska K, Quinn CT, Clapp K, McGann PT (2020) Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease. Am J Hematol 95:E338\u2013E339. https:\/\/doi.org\/10.1002\/ajh.26002","journal-title":"Am J Hematol"},{"key":"5736_CR17","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood.V92.9.3082","volume":"92","author":"JC Bernini","year":"1998","unstructured":"Bernini JC, Rogers ZR, Sandler ES et al (1998) Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating Sickle Cell Disease. Blood 92:3082\u20133089. https:\/\/doi.org\/10.1182\/blood.V92.9.3082","journal-title":"Blood"},{"key":"5736_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/MPH.0b013e3181647bb2","volume":"30","author":"MS Isakoff","year":"2008","unstructured":"Isakoff MS, Lillo JA, Hagstrom JN (2008) A single-Institution experience with treatment of severe acute chest syndrome: lack of Rebound Pain with Dexamethasone plus Transfusion Therapy. J Pediatr Hematol Oncol 30:322\u2013325. https:\/\/doi.org\/10.1097\/MPH.0b013e3181647bb2","journal-title":"J Pediatr Hematol Oncol"},{"key":"5736_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21565","author":"A Sobota","year":"2009","unstructured":"Sobota A, Graham DA, Heeney MM, Neufeld EJ (2009) Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission. Am J Hematol NA-NA. https:\/\/doi.org\/10.1002\/ajh.21565","journal-title":"Am J Hematol NA-NA"},{"key":"5736_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/pbc.23221","volume":"58","author":"A Sobota","year":"2012","unstructured":"Sobota A, Graham DA, Neufeld EJ, Heeney MM (2012) Thirty-day readmission Rates following hospitalization for Pediatric Sickle Cell Crisis at Freestanding Children\u2019s hospitals: risk factors and hospital variation. Pediatr Blood Cancer 58:61\u201365. https:\/\/doi.org\/10.1002\/pbc.23221","journal-title":"Pediatr Blood Cancer"},{"key":"5736_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/pbc.21336","volume":"50","author":"JJ Strouse","year":"2008","unstructured":"Strouse JJ, Takemoto CM, Keefer JR et al (2008) Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease: acute chest syndrome in Sickle Cell Disease. Pediatr Blood Cancer 50:1006\u20131012. https:\/\/doi.org\/10.1002\/pbc.21336","journal-title":"Pediatr Blood Cancer"},{"key":"5736_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1513\/AnnalsATS.202207-627PS","volume":"20","author":"RT Cohen","year":"2023","unstructured":"Cohen RT, Klings ES (2023) Systemic steroids and the risk of vasoocclusive events in patients with Sickle Cell Disease. Ann Am Thorac Soc 20:18\u201320. https:\/\/doi.org\/10.1513\/AnnalsATS.202207-627PS","journal-title":"Ann Am Thorac Soc"},{"key":"5736_CR23","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1182\/blood.2022016070","volume":"139","author":"S Lanzkron","year":"2022","unstructured":"Lanzkron S, Pecker L (2022) Pain without gain: steroids and sickle crisis. Blood 139:3678\u20133679. https:\/\/doi.org\/10.1182\/blood.2022016070","journal-title":"Blood"},{"key":"5736_CR24","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1182\/blood.2021014473","volume":"139","author":"O Walter","year":"2022","unstructured":"Walter O, Cougoul P, Maquet J et al (2022) Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease. Blood 139:3771\u20133777. https:\/\/doi.org\/10.1182\/blood.2021014473","journal-title":"Blood"},{"key":"5736_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","volume":"127","author":"D Zhang","year":"2016","unstructured":"Zhang D, Xu C, Manwani D, Frenette PS (2016) Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood 127:801\u2013809. https:\/\/doi.org\/10.1182\/blood-2015-09-618538","journal-title":"Blood"},{"key":"5736_CR26","unstructured":"Molina Healthcare (2020) Adakveo (crizanlizumab-tmca). Drug and biologic coverage criteria"},{"key":"5736_CR27","unstructured":"Centene Corporation (2020) Clinical policy. Crizanlizumab-tmca (Adakveo"},{"key":"5736_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/antib7010014","volume":"7","author":"T F\u00fcl\u00f6p","year":"2018","unstructured":"F\u00fcl\u00f6p T, M\u00e9sz\u00e1ros T, Kozma G et al (2018) Infusion reactions Associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H. Antibodies 7:14. https:\/\/doi.org\/10.3390\/antib7010014","journal-title":"Antibodies"},{"key":"5736_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.anai.2019.04.015","volume":"123","author":"D Hong","year":"2019","unstructured":"Hong D, Sloane DE (2019) Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases. Ann Allergy Asthma Immunol 123:35\u201341. https:\/\/doi.org\/10.1016\/j.anai.2019.04.015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"5736_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","volume":"142","author":"GAC Isabwe","year":"2018","unstructured":"Isabwe GAC, Garcia Neuer M, de las Vecillas Sanchez L et al (2018) Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol 142:159\u2013170e2. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.018","journal-title":"J Allergy Clin Immunol"},{"key":"5736_CR31","doi-asserted-by":"publisher","first-page":"e20476","DOI":"10.1371\/journal.pone.0020476","volume":"6","author":"R Boulkedid","year":"2011","unstructured":"Boulkedid R, Abdoul H, Loustau M et al (2011) Using and reporting the Delphi Method for Selecting Healthcare Quality indicators: a systematic review. PLoS ONE 6:e20476. https:\/\/doi.org\/10.1371\/journal.pone.0020476","journal-title":"PLoS ONE"},{"key":"5736_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.1995.03530080048040","volume":"274","author":"RL Kravitz","year":"1995","unstructured":"Kravitz RL, Laouri M, Kahan JP et al (1995) Validity of Criteria used for detecting underuse of coronary revascularization. JAMA 274:632\u2013638","journal-title":"JAMA"},{"key":"5736_CR33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM200103013440906","volume":"344","author":"H Hemingway","year":"2001","unstructured":"Hemingway H, Crook AM, Feder G et al (2001) Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med 344:645\u2013654","journal-title":"N Engl J Med"},{"key":"5736_CR34","doi-asserted-by":"publisher","unstructured":"Patel MR, Dehmer GJ, Hirshfeld JW ACCF\/SCAI\/STS\/, AATS\/AHA\/ASNC\/HFSA\/SCCT et al (2012) 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 59:857\u2013881. https:\/\/doi.org\/10.1016\/j.jacc.2011.12.001","DOI":"10.1016\/j.jacc.2011.12.001"},{"key":"5736_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.amjcard.2015.03.057","volume":"116","author":"SM Bradley","year":"2015","unstructured":"Bradley SM, Chan PS, Hartigan PM et al (2015) Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial). Am J Cardiol 116:167\u2013173. https:\/\/doi.org\/10.1016\/j.amjcard.2015.03.057","journal-title":"Am J Cardiol"},{"key":"5736_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1472-6963-6-24","volume":"6","author":"J Ma Quintana","year":"2006","unstructured":"Ma Quintana J, Escobar A, Bilbao A (2006) Explicit criteria for prioritization of cataract surgery. BMC Health Serv Res 6:24. https:\/\/doi.org\/10.1186\/1472-6963-6-24","journal-title":"BMC Health Serv Res"},{"key":"5736_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2105\/ajph.77.2.187","volume":"77","author":"NJ Merrick","year":"1987","unstructured":"Merrick NJ, Fink A, Park RE et al (1987) Derivation of clinical indications for carotid endarterectomy by an expert panel. Am J Public Health 77:187\u2013190. https:\/\/doi.org\/10.2105\/ajph.77.2.187","journal-title":"Am J Public Health"},{"key":"5736_CR38","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJM199806253382607","volume":"338","author":"PG Shekelle","year":"1998","unstructured":"Shekelle PG, Kahan JP, Bernstein SJ et al (1998) The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 338:1888\u20131895. https:\/\/doi.org\/10.1056\/NEJM199806253382607","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05736-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:07:55Z","timestamp":1715580475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05736-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5736"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05736-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"JK declares: consulting fees \u2013 Novartis, Bluebird Bio, GSK, Graphite Bio, Affimmune, Glycomimetics, Johnson and Johnson; presentations\u2013 Medscape; participation on a Data Safety Monitoring Board\/Advisory board \u2013 Novartis, Oric, Magenta, NovoNordisk, Austin Pharmaceuticals, Bristol Myers Squibb, Sanofi; President of the National Alliance of Sickle Cell Centers (501c3 corporation, unpaid). KIA declares: grants or contracts \u2013 NHLBI, US Food and Drug Administration, Novartis, Shire\/Takeda, Forma Therapeutics; consulting fees \u2013 Roche; payment or honoraria for lectures, presentations, speakers bureaus \u2013 Novartis, NovoNordisk, Forma Therapeutics, Roche, Biomarin, Pfizer, Sanofi, Fulcrum Therapeutics; support for attending meetings and\/or travel \u2013 Forma Therapeutics; participation on a Data Safety Monitoring Board or Advisory board \u2013 Vertex. NB declares: honoraria \u2013 Novartis. SG declares: consulting fees \u2013 Novartis. AK declares: consulting fees \u2013 Novartis, GBT, Vertex, Bluebird Bio; honoraria \u2013 GBT, American Society of Hematology; grants or contracts \u2013 NIH\/NHLBI, Novartis, Akira Bio, Forma Therapeutics; participation in Data Safety Monitoring Board\/Advisory Board \u2013 Bluebird Bio, REACH, PUSH-UP. SL declares: grants or contracts to institution research funding \u2013 Imara, GBT, Takeda, CSL-Behring, HRSA, PCORI, MD CHCR; consulting \u2013 Bluebird bio, Novo Nordisk, Pfizer; payment or honoraria for lectures, presentations, or speakers bureaus \u2013 Novartis; participation in a Data Safety Monitoring Board or Advisory Board \u2013 Magenta; stock or stock options \u2013 Pfizer, Teva. DM declares: consulting fees \u2013 Novartis. PM declares: honoraria \u2013 Novartis. SS declares: grants or contracts to institution \u2013 Alexion; consulting fees \u2013 Alexion, Argenx, Cellics, AI proteins; lectures, presentations, speakers bureaus \u2013 Grifols. VNT declares: consulting fees\u2013 bluebird bio, Novartis, Vertex Pharmaceuticals, Blueprint Medicines, Global Blood Therapeutics, Piper Sandler; Forma Therapeutics; honoraria \u2013 Perkin Elmer, American Society of Hematology; research funding \u2013 NIH (NHLBI). IY, CC, MSB declare they are employees of PHAR, which was paid by Novartis to conduct the research described in this manuscript. PHAR also discloses other relationships and activities with: Amgen, BioMarin Pharmaceuticals, Bristol-Meyers Squibb, Celgene, Delfi Diagnostics, Dompe, Eisai, Exact Sciences, Genentech, Gilead, GRAIL, Greenwich Biosciences, Ionis, Jazz, Nobelpharma, Novartis, Otsuka, Pfizer, Recordati, Regeneron, Sanofi, and Takeda outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}